Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Solid Tumors 1ALK-positive Advanced NSCLC 1

Interventions

somatostatin receptor 2 1lenvatinib 1ensartinib 1Nivolumab 1Lutetium 1Injections 1Immune Checkpoint Inhibitors 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Solid Tumors × ensartinib × Clear all
NCT06762327 2025-01-07

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

Nanjing First Hospital, Nanjing Medical University

Phase 2 Not yet recruiting
20 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡